NIH: mRNA vaccine generates immune response in older adults

An experimental mRNA vaccine for the COVID-19 virus generated a strong immune response in older adults in a phase 1 clinical trial, who generally tolerated it well, the National Institutes of Health reports.
The National Institute of Allergy and Infectious Diseases developed the vaccine with Moderna Inc.
The phase 1 trial began in March and later added 40 healthy adults over age 55, who received two doses and will be followed for a year to monitor the long-term effects of the vaccine. According to the researchers, the results support testing the vaccine in older adults in an ongoing large Phase 3 trial.
Related News Articles
Headline
The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
The Occupational Safety and Health Administration June 30 released a proposed rule to remove what remains of its emergency temporary standard for occupational…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…
Headline
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England…
Headline
A study published April 8 by the Public Library of Science’s Journal of Global Public Health found that driving while infected with COVID-19 raises the risk of…
Headline
The Senate Finance Committee Feb. 4 voted 14-13 to advance Robert F. Kennedy Jr.’s nomination for secretary of the Department of Health and Human Services. A…